Anticoagulants Causing Adverse Effects in Therapeutic Use
5
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
8 treatments under study, led by Rivaroxaban
Research Leaders
10 sponsors active, led by MITERA Children's Hospital
Related Conditions
Often studied with 13 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (5)
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study
Social-software iMproving wARfarin Therapy
Atrial Fibrillation: Risk and Benefits of Anti-coagulation in the Elderly
Research Network
Common Treatments
- Rivaroxaban2
- Warfarin1
- Anticoagulants1
- Socialsoftware Management1
- Edoxaban1
Active Sponsors
- MITERA Children's Hospital1
- Karolinska Institutet1
- Malmö University1
- Onassis Cardiac Surgery Centre1
- Region Skane1
Top Investigators
Wuhan Asia Heart Hospital
Faculty of Odontology, Malmö University
AHEPA University Hospital
Karolinska Institutet
Related Conditions
- Frail Elderly Syndrome1
- Hemorrhage1
- Atrial Arrhythmia1
- Congenital Heart Disease1
- Postoperative Complications1